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ABSTRACT
In this study, we set out to determine the frequency and
severity of anemia and the corrective interventions used
during adjuvant chemotherapy for breast cancer.
We conducted a retrospective electronic chart
review of 702 patients who received adjuvant breast
cancer chemotherapy at four BC Cancer Agency cen-
tres in 2002 and 2003. For these patients, we recorded
the initial hemoglobin reading and the date of the first
hemoglobin reading in the ranges 110–119 g/L, 100–
109 g/L, 90–99 g/L, and <90 g/L. We also recorded
any discussion about, or delivery of, interventions
for anemia [transfusion, epoetin (EPO) or both].
Median age of the study population was 51 years,
and it varied with chemotherapy type. Among the
patients, 12% had a hemoglobin reading <120 g/L
before the start of chemotherapy. Overall, the propor-
tion of patients with at least one hemoglobin reading
<120 g/L was 78%; <110 g/L, 54%; <100 g/L, 31%;
and <90 g/L, 14%. Depending on chemotherapy type,
a hemoglobin reading <100 g/L occurred in 5% to 54%
of patients. Intervention rates increased as hemoglo-
bin declined. For 99 patients with a hemoglobin read-
ing <90 g/L, a discussion of anemia was documented
in the treatment chart in 49% of cases, a transfusion
was delivered in 23%, EPO was used in 11%, and trans-
fusion and EPO were both delivered in 5%.
Anemia was relatively common and varied with
chemotherapy type. Documentation of a discussion
of anemia occurred in fewer than 20% of the patients
with a hemoglobin reading of 90–99 g/L and in only
half the patients with a hemoglobin reading <90 g/L.
Intervention rates were low at hemoglobin readings
for which randomized trials have shown that inter-
vention can improve quality of life.
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1. INTRODUCTION
Multi-agent chemotherapy has a spectrum of side
effects, including anemia and fatigue. The severity
of anemia and fatigue vary with chemotherapy, dis-
ease type, age, and other factors 1–5. Patients who
develop anemia during cancer therapy report more
fatigue and poorer quality of life 6,7. The treatment of
anemia with growth factor support has been associ-
ated with reduced fatigue and improved quality of
life 8–14.
Physicians treating patients with adjuvant che-
motherapy for breast cancer often focus on poten-
tially life-threatening toxicities such as febrile
neutropenia or toxicities that require immediate
symptomatic intervention or dose reductions, such
as mucositis, diarrhea, or neuropathy. Fatigue and
anemia are often more insidious, but their impact on
quality of life is an important concern for patients
with cancer 15. The frequency and severity of ane-
mia associated with many commonly used adjuvant
chemotherapy regimens for early-stage breast can-
cer have not been well documented. The present
study reports the frequency and severity of anemia
that developed during adjuvant chemotherapy for
breast cancer in patients treated at four Canadian
regional cancer centres, and the interventions for
anemia that were delivered during that chemotherapy.
2. PATIENTS AND METHODS
2.1 Setting and Patients
The BC Cancer Agency (BCCA) manages the budget
for all anti-neoplastic drugs in the Canadian prov-
ince of British Columbia. We used a provincial phar-
macy database to identify women with breast cancer
who had received adjuvant chemotherapy in 2002
and 2003 at any of four BCCA regional cancer centres
(designated A, B, C, and D). Patients were excluded if
the chemotherapy had been administered for meta-
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static disease, if the patient had had prior chemo-
therapy, if fewer than 3 cycles of chemotherapy had
been delivered, or if the chemotherapy had been re-
ceived outside of the four regional cancer centres.
2.2 Data Collection
Using the BCCA electronic health record, a single health
records administrator (CSA) retrospectively reviewed
prospectively-collected chart data. Dates of diagno-
sis, first and last adjuvant chemotherapy, pre-chemo-
therapy hemoglobin reading, and the first hemoglobin
readings <120 g/L, <110 g/L, <100 g/L, and <90 g/L
were recorded, as were patient age at diagnosis, dis-
ease stage, adjuvant chemotherapy type or types,
treating centre, and name of the attending medical
oncologist. In addition, the data abstractor reviewed
the narrative notes, correspondence, and ancillary
information in the chart and recorded any discussion
of anemia or intervention for anemia (transfusion, use
of growth factor support). A patient who received
epoetin (EPO) or a transfusion was considered to have
had a discussion of anemia.
Dates of interventions for anemia—whether a
discussion, a transfusion, or delivery of EPO—were
recorded and attributed to the interval of the hemo-
globin reading most immediately preceding the date
of intervention. The magnitude of fatigue and of ef-
fects of chemotherapy on quality of life were not re-
corded prospectively and could not be reliably
deduced in retrospect, and so no effort was made to
relate hemoglobin reading or anemia intervention to
quality of life.
2.3 Adjuvant Therapies Evaluated
Adjuvant chemotherapy included these regimens:
• AC: doxorubicin + cyclophosphamide × 4 cycles 16
• CEF: cyclophosphamide + epirubicin + 5-fluorou-
racil × 6 cycles 17
• AC-T/D: AC × 4 cycles, followed by paclitaxel or
docetaxel × 4 cycles 18
• CAF: cyclophosphamide + doxorubicin +
5-fluorouracil
• CMF: cyclophosphamide + methotrexate + 5-fluo-
rouracil 16
• FEC100: 5-fluorouracil + epirubicin 100 mg/m 2
every 3 weeks intravenously + cyclophospha-
mide 19
The most frequently used chemotherapy regimen
was AC. Because AC was not expected to cause much
anemia 16, only a random sample of AC cases was in-
cluded in the analysis. Because the number of patients
treated varied between the four cancer centres, our
analysis included all patients receiving AC at the small-
est centre, a 50% random sample from each of the two
intermediate-size centres, and a 33% random sample
from the largest centre. All patients receiving any of
the other chemotherapy regimens were included.
2.4 Statistical Analyses
All data collected were entered into a searchable da-
tabase. Descriptive statistics were generated. A pa-
tient was counted only the first time she showed a
hemoglobin reading in each of the following ranges:
110–119 g/L, 100–109 g/L, 90–99 g/L, and <90 g/L.
If a patient had a progressively declining hemoglo-
bin reading, she would have contributed data once at
each hemoglobin interval for which she had a read-
ing in the relevant range.
2.5 Declarations
Our study was sponsored by Ortho Biotech Canada and
was approved by the Human Research Ethics Board of
the BCCA and the University of British Columbia.
The sponsor provided funding support only and had
no direct role in data collection, analysis, or interpreta-
tion. The right to approve or disapprove publication of
the manuscript was held by the investigators only.
3. RESULTS
From among an initial 1092 patients identified in the
pharmacy database as having received adjuvant che-
motherapy for breast cancer in 2002 and 2003,
159 patients were excluded because of prior breast
cancer (n = 59), prior chemotherapy (n = 11), treat-
ment outside one of the four BCCA centres (n = 30),
fewer than 3 cycles of chemotherapy (n = 7), or treat-
ment received for recurrent or metastatic disease
(n = 52). Of the remaining 933 cases that were eli-
gible for analysis, 459 had received AC, and 228 of
those were randomly selected for inclusion, yielding
a total analysis sample of 702 patients. Table I sum-
marizes the study cohort’s pertinent demographic and
treatment characteristics.
The use of chemotherapy was similar between
centres, except for somewhat greater use of AC or CMF
chemotherapy at centre C, in part because older
women formed a greater proportion of the patients
treated at that centre (Table II).
Anemia (hemoglobin < 100 g/L) was associated
with chemotherapy type and patient age (Table III).
The severity of the anemia increased with the dura-
tion of chemotherapy (Figure 1). When corrected for
the type of chemotherapy used, the proportion of
patients developing a hemoglobin reading of
<100 g/L was similar between the treating centres
(data not shown).
3.1 Interventions for Anemia
Figure 2 shows the proportions of patients with he-
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that a transfusion or EPO, or both, were prescribed.
Evidence that a discussion of anemia had occurred
during an outpatient visit to a BCCA centre was found
for 15% of patients with a hemoglobin reading in the
range 90–99 g/L (n = 28) and for 49% of patients with
a hemoglobin reading of <90 g/L (n = 49). The re-
spective proportions of those patients receiving a
transfusion were 0.93% (n = 2) and 23% ( n = 23),
receiving EPO were 5% (n = 10) and 11% ( n = 11),
and receiving both were 0.93% (n = 2) and 8%
(n = 8).
3.2 Interventions for Anemia Among Patients
Receiving CEF
Patients receiving CEF chemotherapy most consis-
tently developed anemia (hemoglobin < 100 g/L) and
severe anemia (hemoglobin < 90 g/L). Figure 3
shows the proportion of patients receiving CEF whose
chart showed evidence of a discussion or interven-
tion for anemia at the various study hemoglobin
ranges. Just 50% of study patients receiving CEF had
evidence of a discussion of anemia in their chart when
their hemoglobin reading fell below 90 g/L. The in-
tervention rates were much lower than the discus-
sion rates shown in Figure 3. Figure 4 shows, for each
BCCA centre, the proportion of patients receiving CEF
who had any intervention (discussion, transfusion,
EPO, or a combination) at the various study hemoglo-
bin ranges. The intervention rate, including discus-
sion of or an intervention for anemia, varied between
the four centres.
4. DISCUSSION
Our study demonstrates that anemia is a common side
effect of adjuvant chemotherapy for breast cancer.
Overall, 31% of patients receiving multi-agent che-
motherapy for early-stage breast cancer at a BCCA
centre showed at least 1 hemoglobin reading below
100 g/L, and 14% showed at least 1 hemoglobin value
below 90 g/L. For CEF and AC-T/D chemotherapy, the
proportions developing anemia (hemoglobin
< 100 g/L) were 54% and 27% respectively, and the
TABLE I Demographic, disease, and treatment characteristics of
702 patients receiving adjuvant chemotherapy for breast cancer at
a BC Cancer Agency facility in 2002 or 2003
Patients [n (%)]
Age (years)
<50 234 (33.3)
50–59 289 (41.2)
60+ 179 (25.5)
T stage
TX 62 (8.8)
T1 259 (36.9)
T2 331 (47.2)
T3 42 (6)
T4 8 (1.1)
Nodal status
N0 231 (32.9)
N1 352 (50.1)
N2 45 (6.4)
N3 18 (2.6)
Nx 56 (8)
Treatment centre
A 70 (10)
B 230 (32.8)
C 158 (22.5)
D 244 (34.8)
Pre-chemotherapy hemoglobin (g/L)
<120 83 (11.8)
³120 619 (88.2)
Chemotherapy type
AC 228 (32.5)
CEF 325 (46.3)
AC-T/D 55 (7.8)
CAF 46 (6.6)
CMF 31 (4.4)
FEC100 17 (2.4)
AC = doxorubicin + cyclophosphamide; CEF = cyclophosphamide +
epirubicin + 5-fluorouracil; AC-T/D = doxorubicin + cyclophospha-
mide followed by paclitaxel or docetaxel; CAF = cyclophospha-
mide + doxorubicin + 5-fluorouracil;  CMF = cyclophosphamide +
methotrexate + 5-fluorouracil; FEC100 = 5-fluorouracil + epirubicin
100 mg/m2 every 3 weeks intravenously + cyclophosphamide.
TABLE II Selected demographic and treatment characteristics for 702 patients receiving adjuvant chemotherapy for breast cancer
Centre Patients Median Age CEF AC-T/DA C  or CMF Hemoglobin
(n) age <50 years >60 years [n (%)] [n (%)] [n (%)] <100 g/L
(years) [n (%)] [n (%)] [n (%)]
All 702 51 234 (33.3) 179 (25.5) 325 (46.3) 55 (7.8) 259 (36.9) 215 (30.6)
A 70 49 28 (40.0) 16 (22.9) 34 (48.6) 8 (11.4) 19 (27.1) 13 (18.6)
B 230 50 84 (36.5) 57 (24.8) 120 (52.2) 15 (6.5) 77 (33.5) 90 (39.1)
C 158 53 35 (22.2) 51 (32.3) 62 (39.2) 4 (2.5) 78 (49.4) 30 (9)
D 244 50 87 (35.7) 55 (22.5) 109 (44.7) 28 (11.5) 85 (34.8) 82 (33.6)
CEF = cyclophosphamide + epirubicin + 5-fluorouracil; AC-T/D = doxorubicin + cyclophosphamide followed by paclitaxel or docetaxel; AC =
doxorubicin + cyclophosphamide; CMF = cyclophosphamide + methotrexate + 5-fluorouracil.
a discussion of anemia was recorded in the narrative
notes of the patient’s BCCA chart. It also shows the
proportions of patients whose chart showed evidenceGOLDRICK et al.
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proportions developing severe anemia (hemoglobin
< 90 g/L) were 27% and 7% respectively.
Few data reporting anemia rates with various
adjuvant chemotherapy regimens for breast cancer
are available for comparison with these results. A
retrospective series of patients treated in community
practice with AC chemotherapy reported that 17% of
patients developed anemia (hemoglobin < 100 g/L) 20,
a rate that is substantially higher than the 5% observed
in the current study. In a series of 310 patients with
stage II and III breast cancer treated with adjuvant AC
chemotherapy at eight U.S. centres, 40% showed a
drop in hemoglobin reading to less than 100 g/L dur-
ing the course of treatment 21.
Because the frequency and severity of anemia
varied with chemotherapy type and was most severe
among patients receiving CEF 17 chemotherapy, we
repeated our analysis and cross-centre comparisons
for patients receiving CEF chemotherapy (n = 325).
Even when patients were receiving CEF, an adjuvant
program known to be associated with fatigue and
anemia, the charts of only 50% contained a recorded
discussion of anemia when a hemoglobin reading of
<90 g/L was recorded. Documentation that a discus-
sion had occurred varied by treatment centre, rang-
ing from 32% to 83%.
The purpose of the present study was not to de-
termine who should have an intervention for anemia
TABLE III Numbers and proportions of patients developing various severities of anemia during adjuvant chemotherapy for breast cancer
Patients Hemoglobin {g/L [n (%)]}
[n (%)] <120 <110 <100 <90
(n=545) (n=380) (n=215) (n=99)
All 702
Chemotherapy
CEF 325 (46.3) 319 (98.2) 272 (83.7) 175 (53.8) 86 (26.5)
AC-T/D 55 (7.8) 45 (81.8) 31 (56.4) 15 (27.3) 4 (7.3)
AC 228 (32.5) 120 (52.6) 44 (19.3) 11 (4.8) 3 (1.3)
CMF 31 (4.4) 16 (51.6) 8 (25.8) 3 (9.7) 3 (9.7)
CAF 46 (6.6) 31 (67.4) 18 (39.1) 9 (19.6) 3 (6.5)
FEC100 17 (2.4) 14 (82.4) 7 (41.2) 2 (11.8) 0
Centre
A 70 (10) 53 (75.7) 30 (42.9) 13 (18.6) 6 (8.6)
B 230 (32.8) 185 (80.4) 145 (63.0) 90 (39.1) 42 (18.3)
C 158 (22.5) 115 (72.8) 142 (89.9) 82 (51.9) 42 (26.6)
D 244 (34.8) 192 (78.7) 63 (25.8) 30 (12.3) 9 (3.7)
Age (years)
<50 234 (33.3) 200 (85.5) 143 (61.1) 78 (33.3) 37 (15.8)
³50 468 (66.7) 345 (73.7) 237 (50.6) 137 (29.3) 62 (13.2)
CEF = cyclophosphamide + epirubicin + 5-fluorouracil; AC-T/D = doxorubicin + cyclophosphamide followed by paclitaxel or docetaxel; AC =
doxorubicin + cyclophosphamide; CMF = cyclophosphamide + methotrexate + 5-fluorouracil;  CAF = cyclophosphamide + doxorubicin + 5-
fluorouracil; FEC100 = 5-fluorouracil + epirubicin 100 mg/m2 every 3 weeks intravenously + cyclophosphamide.
FIGURE 1 Median duration between the start of chemotherapy and
first hemoglobin (Hgb) reading at each level (patients with a pre-
chemotherapy Hgb < 120 g/L were excluded).
FIGURE 2 The proportion of patients having a discussion of, or
intervention for, anemia increased at lower hemoglobin (Hgb)
levels.ANEMIA IN ADJUVANT CHEMOTHERAPY
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or whether intervention improves quality of life. The
2002 American Society of Clinical Oncology/Ameri-
can Society of Hematology guideline on the use of
EPO in patients with chemotherapy-associated anemia
recommends treatment at a hemoglobin reading of
<100 g/L 8. This grade B recommendation is based on
level II evidence. In patients with less severe anemia
(hemoglobin 100–120 g/L), the guideline recom-
mends that treatment decisions be guided by an evalu-
ation of the clinical manifestations of anemia,
including its effect on the patient’s functional capac-
ity and quality of life (grade C recommendation) 8.
Anemia is a relatively neglected side effect of
adjuvant chemotherapy. In the present study, the treat-
ment records of only 15% of patients with a hemo-
globin reading of 90–99 g/L and 49% of those with a
hemoglobin reading <90 g/L contained evidence that
anemia had at least been discussed. The therapeutic
intervention rate (transfusion or EPO, or both) was even
lower: 6.5% (n = 14) for patients with a hemoglobin
reading of 90–99 g/L and 42% (n = 42) for patients
with a hemoglobin reading of <90 g/L. Relatively low
rates of intervention have also been reported in other
studies 7,22. In the European Cancer Anemia Survey
(ECAS), which prospectively collected data on the inci-
dence and prevalence of anemia in more than 15,000
cancer patients with various malignancies (includ-
ing more than 3000 with breast cancer), 30% of the
breast cancer patients were anemic (hemoglobin
< 120 g/L) at survey enrolment 5. Anemia rates var-
ied by tumour type, disease status, and cancer treat-
ment status. In the ECAS study, 19% of patients with
breast cancer who had anemia received either a trans-
fusion or EPO, or a combination. Low hemoglobin
levels correlated with poor performance status.
A number of reasons may account for the low
rates observed in the current study of discussion of
anemia and of intervention to correct the condition.
Some patients may not have been symptomatic with
a hemoglobin reading of <100 g/L or <90 g/L (an
unlikely situation) 9,10. Some anemic patients may
have been close to chemotherapy completion, and
their physicians may have felt that they would re-
cover without specific intervention. A discussion of
anemia may have taken place, but may not have been
recorded in the chart. (A retrospective evaluation of
the latter circumstance is impossible, but the narra-
tive notes were frequently lengthy, recording many
other details of the patient’s cancer, treatment-related
symptoms, and social circumstances.) The cost of
treatment may have been another factor. The BCCA
funds all anti-neoplastic drugs in the province, in-
cluding the cost to deliver chemotherapy, but it does
not fund supportive medications, including anti-
emetics, analgesics, or growth factor support. Sup-
portive medications are the responsibility of the
patient or of her extended health coverage provider.
The likelihood that oncologists would discuss ane-
mia and offer interventions if growth factor support
were free of direct charge to the patient is unknown.
Considerable debate exists about the ethics of dis-
cussing or withholding details about drug treatments
that are not funded within a system of otherwise uni-
versal coverage 23,24.
Physicians and patients are increasingly reluctant
to use transfusions for self-limited anemia, despite
the reduction in risk of viral transmission with im-
proved screening. Some physicians may be reluctant
to use growth factor support because of concerns
about compromising outcome during curative treat-
ment, given that erythropoietin receptors have been
reported to be present on some breast cancer cells 25,26,
and endogenous erythropoietin may inhibit hypoxia-
induced apoptosis of breast cancer cells 27. These
complex issues all need to be considered before in-
tervention for anemia and fatigue are recommended,
but the consideration starts with recognizing that ane-
FIGURE 3 Discussion of or treatment for anemia in patients receiving
CEF (cyclophosphamide + epirubicin + 5-fluorouracil) chemo-
therapy (n = 325), by hemoglobin (Hgb) level.
FIGURE 4 Rates of discussion of or intervention for anemia in
patients receiving CEF (cyclophosphamide + epirubicin + 5-fluo-
rouracil) chemotherapy (n = 325), by cancer centre. Hgb = hemo-
globin; A, B, C, D = the four study centres.GOLDRICK et al.
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mia and fatigue are a relatively common side effect
of adjuvant chemotherapy.
Since this study was completed, the use of CEF
chemotherapy has declined considerably, and some
BCCA centres have adopted a practice of having the
ambulatory care nurse review the patient’s hemoglo-
bin reading before each cycle of chemotherapy, dis-
cuss quality-of-life issues with the patient, and
highlight the level of fatigue, if present, to the at-
tending oncologist if the hemoglobin reading is below
100 g/L. These measures have the potential to in-
crease awareness of chemotherapy-related anemia as
an adverse effect on the patient’s function and qual-
ity of life. Whether this approach will ultimately in-
crease the rate of interventions to correct anemia and
improve quality of life or compliance with planned
treatment during adjuvant chemotherapy for breast
cancer warrants prospective evaluation.
5. CONCLUSIONS
In breast cancer patients undergoing adjuvant che-
motherapy, anemia was relatively common and var-
ied with chemotherapy type. Documentation of a
discussion of anemia occurred in fewer than 20% of
the patients with a hemoglobin reading of 90–99 g/L
and in only half the patients with a hemoglobin read-
ing of <90 g/L. Intervention rates were low at hemo-
globin readings for which randomized trials have
shown that intervention can improve quality of life.
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